519028-33-2

Basic information

• Product Name: Benzyl (2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate
• Synonyms: 519028-33-2;Benzyl (2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate;Benzyl 2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-ylcarbamate;benzyl N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-6-oxo-1H-pyrimidin-2-yl]propan-2-yl]carbamate;SCHEMBL5119942;C23H23FN4O5;MFCD30489073;SC5114;SB60410;DS-19469;CS-0162377;A924249;Benzyl(2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate
• CAS NO: 519028-33-2
• Molecular Weight: 454.458
• EINECS: -0
• Mol File: 519028-33-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzyl (2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl (2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate(519028-33-2)
• EPA Substance Registry System: Benzyl (2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate(519028-33-2)

Safety Data

• Hazardous Substances Data: 519028-33-2(Hazardous Substances Data)

Usage

General Description

Benzyl (2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate is a complex chemical compound with a long name. It is a carbamate derivative with a benzyl group and a dihydropyrimidin-2-yl moiety. The compound also contains a carbamoyl group and a 4-fluorobenzyl group. It may have potential applications in medicinal chemistry, particularly in the development of pharmaceutical drugs. Further research is needed to fully understand the properties and potential uses of this chemical compound.

Upstream product

• 519032-08-7 methyl 2-(1-{[(benzyloxy) carbonyl] amino}-1-methylethyl)-5,6-dihydroxypyrimidine-4-carboxylate 
• 140-75-0 para-fluorobenzylamine 
• 1064707-10-3 C₁₈H₂₃N₃O₇ 
• 1028026-73-4 C₁₈H₂₃N₃O₇ 
• 518047-98-8 [1-(N'-hydroxycarbamimidoyl)-1-methyl-ethyl]carbamic acid benzyl ester 
• 501-53-1 benzyl chloroformate 
• 100134-82-5 (cyano-dimethyl-methyl)carbamic acid benzyl ester 
• 1064707-10-3 2-[(2-benzyloxycarbonylamino-2-methyl-propionimidoyl)-aminooxy]-but-2-enedioic acid dimethyl ester 
• 518047-98-8 benzyl [2-amino-2-(hydroxyimino)-1,1-dimethylethyl]carbamate 

Downstream Products

• 519028-41-2 2-(1-amino-1-methylethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide 
• 519028-28-5 5,6-dihydroxy-2-(1-methyl-1-methylamino-ethyl)-pyrimidine-4-carboxylic acid 4-fluoro-benzylamide 
• 519032-35-0 2-(1-benzylamino-1-methyl-ethyl)-5,6-dihydroxy-pyrimidine-4-carboxylic acid 4-fluoro-benzylamide 
• 519032-37-2 2-{1-[benzyl(methyl)amino]-1-methylethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide 
• 518048-02-7 {1-[4-(4-fluoro-benzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidin-2-yl]-1-methyl-ethyl}carbamic acid benzyl ester 
• 518048-05-0 raltegravir 
• 1328839-28-6 C₂₄H₂₃FN₈O₇ 
• 1172131-65-5 C₂₉H₃₃FN₄O₆ 
• 1172131-64-4 2,2-dimethyl-propionic acid 2-(1-amino-1-methyl-ethyl)-4-(4-fluorobenzylcarbamoyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-5-yl ester 
• 1172131-66-6 C₂₅H₂₉FN₆O₆ 
• 519028-40-1 C₂₄H₂₅FN₄O₅ 
• 518048-03-8 2-(1-amino-1-methyl-ethyl)-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-4-pyrimidinecarboxamide 

Relevant articles and documents

Development of a second-generation, highly efficient manufacturing route for the HIV integrase inhibitor raltegravir potassium

A manufacturing route for the synthesis of raltegravir potassium 1 was developed via a thermal rearrangement of amidoxime DMAD adducts 6 to construct the key, highly functionalized hydroxypyrimidinone core 7. Utilizing this route 1 was prepared in nine linear chemical steps with 22% overall yield. A second-generation synthesis was subsequently developed that solved the key chemical, productivity, and environmental impact issues of the initial synthesis. Highlights of the new synthesis include a highly selective methylation, 3-4-fold higher productivity, and a 65% reduction of combined organic and aqueous waste produced. The efficient second-generation manufacturing route provides raltegravir potassium 1 in 35% overall yield.

Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors

Human immunodeficiency virus type-1 (HIV-1) integrase, one of the three constitutive viral enzymes required for replication, is a rational target for chemotherapeutic intervention in the treatment of AIDS that has also recently been confirmed in the clinical setting. We report here on the design and synthesis of N-benzyl-5,6-dihydroxypyrimidine-4-carboxamides as a class of agents which exhibits potent inhibition of the HIV-integrase-catalyzed strand transfer process. In the current study, structural modifications on these molecules were made in order to examine effects on HIV-integrase inhibitory potencies. One of the most interesting compounds for this series is 2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 38, with a CIC95 of 78 nM in the cell-based assay in the presence of serum proteins. The compound has favorable pharmacokinetic properties in preclinical species (rats, dogs, and monkeys) and shows no liabilities in several counterscreening assays, highlighting its potential as a clinically useful antiviral agent.